136191 20260217205544.0 doi 10.1007/s00345-024-05092-0 sideral 139106 ART-2024-139106 eng Morote, Juan External validation of the barcelona magnetic resonance imaging predictive model for detecting significant prostate cancer including men receiving 5-alpha reductase inhibitors 2024 Access copy available to the general public Unrestricted Purpose : To validate the Barcelona-magnetic resonance imaging predictive model (BCN-MRI PM) for clinically significant prostate cancer (csPCa) in Catalonia, a Spanish region with 7.9 million inhabitants. Additionally, the BCN-MRI PM is validated in men receiving 5-alpha reductase inhibitors (5-ARI). Materials and methods : A population of 2,212 men with prostate-specific antigen serum level > 3.0 ng/ml and/or a suspicious digital rectal examination who underwent multiparametric MRI and targeted and/or systematic biopsies in the year 2022, at ten participant centers of the Catalonian csPCa early detection program, were selected. 120 individuals (5.7%) were identified as receiving 5-ARI treatment for longer than a year. The risk of csPCa was retrospectively assessed with the Barcelona-risk calculator 2 (BCN-RC 2). Men undergoing 5-ARI treatment for less than a year were excluded. CsPCa was defined when the grade group was ≥ 2. Results: The area under the curve of the BCN-MRI PM in 5-ARI naïve men was 0.824 (95% CI 0.783–0.842) and 0.849 (0.806–0.916) in those receiving 5-ARI treatment, p 0.475. Specificities at 100, 97.5, and 95% sensitivity thresholds were to 2.7, 29.3, and 39% in 5-ARI naïve men, while 43.5, 46.4, and 47.8%, respectively in 5-ARI users. The application of BCN-MRI PM would result in a reduction of 23.8% of prostate biopsies missing 5% of csPCa in 5-ARI naïve men, while reducing 25% of prostate biopsies without missing csPCa in 5-ARI users. Conclusions The BCN-MRI PM has achieved successful validation in Catalonia and, notably, for the first time, in men undergoing 5-ARI treatment. info:eu-repo/grantAgreement/ES/ISCIII/PI20/01666 info:eu-repo/semantics/openAccess by https://creativecommons.org/licenses/by/4.0/deed.es 2.9 2024 UROLOGY & NEPHROLOGY 34 / 133 = 0.256 2024 Q2 T1 1.055 2024 Urology 2024 Q1 5.4 2024 info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion Borque-Fernando, Ángel Universidad de Zaragoza (orcid)0000-0003-0178-4567 Esteban, Luis M. (orcid)0000-0002-3007-302X Picola, Natàlia Muñoz-Rodriguez, Jesús Paesano, Nahuel Ruiz-Plazas, Xavier Muñoz-Rivero, Marta V. Celma, Ana Manuel, Gemma García-de Miró, Berta Abascal, José M. Servian, Pol 1013 817 Universidad de Zaragoza Dpto. Cirugía Área Urología 42, 393 (2024), [8 pp.] World j. urol. World journal of urology 0724-4983 2026375 http://zaguan.unizar.es/record/136191/files/texto_completo.pdf Versión publicada 2172832 http://zaguan.unizar.es/record/136191/files/texto_completo.jpg?subformat=icon icon Versión publicada oai:zaguan.unizar.es:136191 articulos driver 2026-02-17-20:37:46 ARTICLE